Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Combination of Avelumab and Taxane Based Chemotherapy in Platinum Refractory or Ineligible Metastatic Urothelial Cancer

Next Previous
Trial Profile

A Phase 1b Study of Combination of Avelumab and Taxane Based Chemotherapy in Platinum Refractory or Ineligible Metastatic Urothelial Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Docetaxel (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Squamous cell cancer; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AVETAX

Most Recent Events

  • 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
  • 01 Sep 2021 Planned End Date changed from 28 Feb 2021 to 23 Feb 2026.
  • 01 Sep 2021 Planned primary completion date changed from 28 Feb 2021 to 23 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top